Omnitrope is a synthetic human growth hormone added to some IVF protocols to help the ovaries respond better to stimulation medications. It’s most commonly prescribed for patients whose ovaries have responded poorly in previous cycles, with the goal of improving egg quality and increasing the number of usable embryos. Its use in IVF is off-label, meaning the FDA has not approved it for fertility treatment, but fertility clinics use it based on growing clinical evidence.
How Omnitrope Works in the Ovaries
Omnitrope’s active ingredient, somatropin, is identical to the growth hormone your body naturally produces. When injected, it stimulates the liver to produce a protein called insulin-like growth factor-1 (IGF-1). This protein is the real workhorse in fertility applications: IGF-1 enhances the ovaries’ responsiveness to FSH, the primary hormone used during IVF stimulation to grow follicles. In simple terms, it helps the ovaries “listen” better to the medications already being used.
Human egg cells and the surrounding support cells have growth hormone receptors on their surface, so Omnitrope also acts directly on developing follicles. Animal studies have shown that growth hormone improves egg quality by enhancing mitochondrial function, essentially giving eggs more cellular energy to develop properly. Without adequate growth hormone signaling, egg maturation can be impaired.
Who Gets Prescribed Omnitrope
Most fertility clinics reserve Omnitrope for patients categorized as “poor responders,” meaning their ovaries produced fewer eggs or follicles than expected during a previous stimulation cycle. This group typically includes women over 35 with diminished ovarian reserve, patients with a low antral follicle count on ultrasound, or those who needed high doses of stimulation medications but still yielded few eggs. Some clinics also offer it to patients who had eggs retrieved in prior cycles but saw poor embryo development.
It is not a standard part of every IVF protocol. If your ovaries respond normally to stimulation, the added cost and injections generally aren’t justified. Your clinic will assess your specific history and ovarian reserve markers to determine whether adding growth hormone makes sense for your cycle.
Impact on Embryo Quality and Chromosomal Health
One of the most promising effects of Omnitrope in IVF is its influence on embryo quality, particularly chromosomal normality. A study published in Frontiers in Endocrinology looked at 208 women undergoing IVF with genetic testing of their embryos. Women who received growth hormone alongside their stimulation medications had a significantly higher rate of chromosomally normal (euploid) blastocysts: 32% compared to just 9.14% in the same women’s previous cycles without growth hormone. When compared to a separate group of patients who never received growth hormone, the euploid rate was still notably higher (32% vs. 21%).
This matters because chromosomally normal embryos are far more likely to implant, sustain a pregnancy, and result in a healthy baby. For patients who have experienced repeated failed transfers or miscarriages tied to embryo quality, this kind of improvement can be meaningful. The effect appears to stem from growth hormone’s ability to boost mitochondrial function in developing eggs, giving them the energy needed for proper cell division.
What to Expect During Treatment
Omnitrope is a subcutaneous injection, meaning you inject it just under the skin, typically in the abdomen or thigh. It’s usually added to your existing stimulation protocol, so you’ll be taking it alongside your other IVF medications rather than as a standalone treatment. Protocols vary by clinic: some start Omnitrope several weeks before a stimulation cycle begins, while others add it on the first day of stimulation and continue through the trigger shot.
The medication comes in a pen-style injector, similar to other fertility medications you may already be using. Your clinic will walk you through preparation and injection technique. For most patients, it adds one extra injection per day to their existing routine.
Off-Label Status
The FDA approved Omnitrope for conditions related to growth hormone deficiency in children and adults, including growth failure, Turner syndrome, and Prader-Willi syndrome. Fertility treatment is not among its approved uses. This means your insurance is unlikely to cover it for IVF, and the cost comes out of pocket. Off-label prescribing is common and legal in medicine; it simply means the drug is being used for a purpose not listed on its FDA label. Many widely used fertility medications started as off-label treatments before accumulating enough clinical evidence.
Possible Side Effects
Because Omnitrope is used for a relatively short period during IVF (days to weeks rather than months or years), side effects tend to be mild. The most commonly reported issues include pain, redness, or numbness at the injection site, headaches, and fluid retention that can cause mild swelling. Some patients experience joint or muscle pain and tingling or numbness in the hands, which can occasionally progress to carpal tunnel syndrome symptoms.
Less common effects include elevated blood sugar and reduced thyroid hormone levels. Your clinic will typically monitor bloodwork during your stimulation cycle, which helps catch any metabolic shifts early. For most patients, side effects resolve quickly once the medication is stopped.